Ray Manneh Kopp
@raymanneh
Followers
1K
Following
5K
Media
51
Statuses
5K
Medical Oncologist focused in Genitourinary tumors
Colombia
Joined December 2011
RT @fmassari79: Out our first translational research from ARON-1α. mRNA expression, tumor heterogeneity, and response to therapy in patient….
0
5
0
RT @PBarataMD: 🌟Join us on Sept 19 for the Cleveland Genitourinary Oncology Consortium Symposium, co-hosted by @UHhospitals & @ClevelandCl….
0
11
0
RT @drenriquegrande: ⚡️ First-ever perioperative systemic therapy to beat surgery alone in MIBC. Pembrolizumab (Keytruda) + Enfortumab vedo….
0
14
0
RT @ozdogan_md: 🚨 FDA grants accelerated approval to oral zongertinib for advanced HER2 TKD-mutant NSCLC. 📊 ORR: 75%, 58% with responses ≥….
0
12
0
RT @g_develasco: 🚨 When EV/pembro is not an option, what's the best first-line strategy for cisplatin-ineligible patients with advanced uro….
ascopubs.org
PURPOSEImmune checkpoint inhibitors combined with platinum-based chemotherapy is standard in patients with advanced/metastatic urothelial carcinoma (mUC). Cisplatin has immunomodulatory benefits...
0
17
0
RT @MLPOncoData: Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-….
thelancet.com
The addition of adjuvant chemotherapy to hormonotherapy conferred no survival benefit in women aged 70 years and above with a GGI high-risk oestrogen receptor-positive HER2-negative breast cancer,...
0
3
0
RT @Ecastromarcos: Germline variants with therapeutic implications in prostate cancer. It has been a pleasure to work with.@BitarafMasoudMD….
0
13
0
Proud to be part of this great initiative! >300 non clear cell renal cell carcinoma patients analyzed!! .
3
17
73
RT @dr_yakupergun: mFOLFIRINOX or S-IROX vs Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611)….
0
45
0
RT @oncodaily: @BourlonMaite @aron_project @DrYukselUrun @PaolaVS94 @drenriquegrande @TresUramigas @fmassari79 @raymanneh @INCMNSZ_Uronco @….
oncodaily.com
Maite Bourlon: Nivolumab Plus Cabozantinib in Metastatic Renal Cell Carcinoma / Alessia Salfi, Aristotelis Bamias, Bohuslav Melichar, cancer, Dipen Bhuva,
0
2
0
RT @BallenDF: Keynote Lecture por @ClaraMontagut que nos ha ayudado a entender el valioso rol de la biopsia líquida en cáncer colorrectal.….
0
7
0
RT @DrMHofman: Finally, a killer application for Y-90 FAPI theranostics? . Near complete metabolic responses in 3 patients with treatment r….
0
36
0
RT @Ecastromarcos: Our last paper in @Annals_Oncology: BRCA and HRR muts have similar prevalence in low and high volume mHSPC, but greater….
0
37
0
RT @TresUramigas: Datos de mutaciones BRCA y HRR en #prostatecancer hormonos sensible .🧑🤝🧑 mut HRR & BRCA similres en alto & bajo volumen….
0
14
0
RT @BourlonMaite: Biggest RWD: Cabo/nivo 1st line #kidneycancer.🔴 N=333, 17 countries & 53 centers @aron_project .🟠 mFU 15.9m, mOS not reac….
0
23
0
RT @APCCC_Lugano: Exercise in patients with metastatic prostate cancer: A comprehensive review. Physical activity🏃….
0
21
0
RT @DrMHofman: "Many lives are lost not because they don't have access to newest technology or drugs, but because they didn't receive prove….
0
13
0
RT @StephenVLiu: FLAURA2 press release: addition of chemotherapy to 1L osimertinib in #EGFR NSCLC improves overall survival. Already approv….
astrazeneca.com
0
60
0
RT @H12Octubre: 👨⚕️ Doctor Luis Paz-Ares, jefe de Oncología Médica del #Hospital12deOctubre, ganador de una ayuda de la @FundacionECR para….
0
27
0
RT @drenriquegrande: ⚡️ New insights into residual #BladderCancer after neoadjuvant therapy:. A scar-like transcriptomic profile may identi….
0
11
0